Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
作者信息
Cazzola Mario
出版信息
Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023.
Abstract
摘要
相似文献
1
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023.
2
The myelodysplastic syndromes and myeloproliferative disorders.
Clin Lab Sci. 2004 Fall;17(4):223-34.
3
Non-infectious pulmonary complications of myelodysplastic syndromes and chronic myeloproliferative disorders.
Rev Mal Respir. 2011 Jun;28(6):e18-27. doi: 10.1016/j.rmr.2009.04.001. Epub 2011 Jun 8.
4
The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.
Leukemia. 2016 Jul;30(7):1624-7. doi: 10.1038/leu.2016.21. Epub 2016 Feb 9.
5
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica. 2011 Oct;96(10):e41-2. doi: 10.3324/haematol.2011.048991.
6
Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Leuk Lymphoma. 2008 Jul;49(7):1225-7. doi: 10.1080/10428190802187189.
7
Progenitor cells and classification of myelodysplastic and myeloproliferative disorders.
Lancet. 1985 Nov 30;2(8466):1240. doi: 10.1016/s0140-6736(85)90764-0.
8
Progenitor cells and classification of myelodysplastic and myeloproliferative disorders.
Lancet. 1985 Oct 19;2(8460):885. doi: 10.1016/s0140-6736(85)90145-x.
9
Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.
Leuk Lymphoma. 2018 Jul;59(7):1742-1745. doi: 10.1080/10428194.2017.1397669. Epub 2017 Nov 8.
10
The WHO classification of the myelodysplastic syndromes.
Exp Oncol. 2004 Sep;26(3):166-9.
引用本文的文献
1
[Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification].
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):445-452. doi: 10.3760/cma.j.cn121090-20231109-00258.
2
Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes.
J Adv Pract Oncol. 2017 Jan-Feb;8(1):29-39. Epub 2017 Jan 1.
3
Refractory thrombocytopenia and neutropenia: a diagnostic challenge.
Mediterr J Hematol Infect Dis. 2015 Feb 18;7(1):e2015018. doi: 10.4084/MJHID.2015.018. eCollection 2015.
4
Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.
Mater Sociomed. 2014 Oct;26(5):292-6. doi: 10.5455/msm.2014.26.292-296. Epub 2014 Oct 29.
5
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.
Curr Hematol Malig Rep. 2013 Dec;8(4):351-60. doi: 10.1007/s11899-013-0172-3.
6
Prognostic factors in myelodysplastic syndromes.
Maedica (Bucur). 2012 Dec;7(4):295-302.
7
Visualising the cross-level relationships between pathological and physiological processes and gene expression: analyses of haematological diseases.
PLoS One. 2013;8(1):e53544. doi: 10.1371/journal.pone.0053544. Epub 2013 Jan 2.
8
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Haematologica. 2013 Apr;98(4):568-75. doi: 10.3324/haematol.2012.071449. Epub 2012 Oct 12.
9
The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
PLoS One. 2012;7(8):e44321. doi: 10.1371/journal.pone.0044321. Epub 2012 Aug 31.
10
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica. 2011 Oct;96(10):e41-2. doi: 10.3324/haematol.2011.048991.
本文引用的文献
1
Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.
Haematologica. 2011 Jan;96(1):8-10. doi: 10.3324/haematol.2010.035519.
2
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
3
Cytogenetic risk stratification in chronic myelomonocytic leukemia.
Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957. Epub 2010 Nov 25.
4
IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.
Haematologica. 2010 Oct;95(10):1623-7. doi: 10.3324/haematol.2010.030015.
5
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.
6
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
J Clin Oncol. 2010 Aug 20;28(24):3858-65. doi: 10.1200/JCO.2009.27.1361. Epub 2010 Jul 19.
7
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nat Genet. 2010 Aug;42(8):665-7. doi: 10.1038/ng.620. Epub 2010 Jul 4.
8
Prognostic classification and risk assessment in myelodysplastic syndromes.
Hematol Oncol Clin North Am. 2010 Apr;24(2):459-68. doi: 10.1016/j.hoc.2010.02.005.
9
Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia.
J Clin Oncol. 2010 Apr 10;28(11):1919-27. doi: 10.1200/JCO.2009.24.4426. Epub 2010 Mar 15.
10
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
Leukemia. 2010 May;24(5):1062-5. doi: 10.1038/leu.2010.20. Epub 2010 Feb 25.
Zotero 插件